Pakistan Medicines & Pharma IntelligenceMedicine data  •  Company portfolios  •  Price records
MedInfoBaseMedicines · Evidence · Intelligence
Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

Epharm Laboratories

Pharmaceutical manufacturer · Pakistan

Database-driven profile Portfolio, price and regulatory-source intelligence derived from MedInfoBase records.
ShareSend this page
Regulatory & corporate identity

Company profile

Not yet verified
Company type
Pharmaceutical manufacturer
DRAP-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000598 144 linked products · source seen 10 Aug 2026 View source ↗
Location intelligence

Company location

Google Maps
Exact site not yet verified

MedInfoBase will not invent a factory or office location. The map appears after a sourced address, Place ID or verified embed URL is added.

Open in Google Maps ↗ The Google Maps search link uses the company name and available city/country context; it is not presented as a verified premises pin.
Intelligence snapshot

Portfolio at a glance

Not sales data · current MedInfoBase database view
Rx144product presentations
G67generic molecules
DF12dosage-form groups
TA14therapeutic areas
PKR144current price records
REG126registration numbers
Data coverage

How complete is this profile?

Current price coverage100%
products with a current official price
Source-linked coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage94%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixEpharm LaboratoriesShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026Anti-infectives82 · 57%Cardiovascular17 · 12%Gastrointestinal & hepatology13 · 9%Vitamins, minerals & nutrition9 · 6%Hematology & thrombosis4 · 3%Respiratory & allergy4 · 3%CNS & mental health3 · 2%Other therapeutic areas12 · 8%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioEpharm LaboratoriesDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026144presentationsTablet59 · 41%Injection29 · 20%Capsule19 · 13%Syrup8 · 6%Drops7 · 5%Suspension7 · 5%Other forms15 · 10%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent-Market Price Position

Shows whether safely comparable products are below, near or above the market median unit price.

Equivalent-Market Price PositionEpharm LaboratoriesCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026136comparable productsBelow market median67 · 49%Near market median48 · 35%Above market median21 · 15%Company median price position-4.7%Lowest-price equivalents19Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsEpharm LaboratoriesCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/epharm-laboratoriesGenerated 10 Aug 2026Nabiqasim Industries (Pvt) Ltd.,42 shared63% overlapMediate Pharmaceutical Pvt Ltd39 shared58% overlapNeutro Pharma (Pvt.) Ltd.,38 shared57% overlapCCL Pharmaceuticals (Pvt.) Ltd.37 shared55% overlapZafa Pharmaceutical Laboratories (P…37 shared55% overlapPharmasol (Pvt) Ltd.36 shared54% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives82 products · 57%
Cardiovascular17 products · 12%
Gastrointestinal & hepatology13 products · 9%
Vitamins, minerals & nutrition9 products · 6%
Hematology & thrombosis4 products · 3%
Respiratory & allergy4 products · 3%
CNS & mental health3 products · 2%
Dermatology2 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Fluoroquinolone antibacterials15 products · 10%
Third-generation cephalosporins14 products · 10%
Antimalarials11 products · 8%
Antifungals9 products · 6%
Vitamins / minerals / hematinics9 products · 6%
First-generation cephalosporins6 products · 4%
Aminoglycoside antibacterials5 products · 3%
Macrolide antibacterials5 products · 3%
Formulation footprint

Dosage forms

Tablet59 products
Injection29 products
Capsule19 products
Syrup8 products
Drops7 products
Suspension7 products
Cream4 products
Infusion4 products
Gel2 products
Ointment2 products
Solution2 products
Pessary1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 KeleyCephalexin 6presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #2 TeltanTelmisartan + Hydrochlorothiazide 5presentations 40 mg + 12.5 mg, 80 mg + 12.5 mg · Tablet #3 AstronMoxifloxacin 4presentations 400 mg, 400 mg/250 mL, 5 mg/mL · Tablet, Infusion, Drops #4 EpanCefixime 4presentations 100 mg/5 mL, 200 mg, 400 mg · Suspension, Capsule #5 FlociprinCiprofloxacin 4presentations 200 mg/100 mL, 250 mg, 500 mg, 750 mg · Infusion, Tablet #6 TaripharmOfloxacin 4presentations 0.3 %, 200 mg, 200 mg/100 mL, 400 mg · Drops, Tablet, Infusion
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median6749% of comparable products
Near market median48within ±5% of median
Above market median2115% of comparable products
Lowest-price equivalents19ties included
Company median price position -4.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Keley 500 mgCephalexin · Capsule · 16's PKR 14.49/capsule-52.9% vs market median Ephagent 40 mg/mLGentamicin · Injection · 2mlx25's PKR 11.85/mL-49.8% vs market median Ephagent 40 mg/mLGentamicin · Injection · 2mlx5's PKR 12.23/mL-48.2% vs market median Conate 1 %Clotrimazole · Cream · 15gm PKR 3.20/g-47.3% vs market median PC-Trax 250 mgCeftriaxone · Injection · 1 Vial PKR 104.84/vial/unit-45.4% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Nabiqasim Industries (Pvt) Ltd.,362 products · 118 generics 42shared generics Mediate Pharmaceutical Pvt Ltd239 products · 90 generics 39shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 38shared generics CCL Pharmaceuticals (Pvt.) Ltd.243 products · 90 generics 37shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.239 products · 98 generics 37shared generics Pharmasol (Pvt) Ltd.251 products · 101 generics 36shared generics
Regulatory & price activity

Observed database signals

Registration numbers126
Price-history records161
Products with price history15
Source records with multiple versions0
Latest MedInfoBase verification9 Aug 2026
Latest effective price date30 Jul 2026
Latest source observation10 Aug 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Sponsored company campaign area · advertising must be clearly disclosed
Complete company portfolio

Products and presentations

82 results
Intelligence filter: Therapeutic areaAnti-infectives Clear intelligence filters
Reset
BrandGenericStrengthFormPackRegistrationOfficial priceUnit priceMarket position
Algixim Cefotaxime 500 mg Injection 1 Vial 047491 PKR 168.48 PKR 168.48/vial/unit 6% above median
Algixim Cefotaxime 1 g Injection 1 Vial 047492 PKR 297.32 PKR 297.32/vial/unit Near median
Algixim Cefotaxime 250 mg IM/IV injection 1 Vial 047490 PKR 97.08 PKR 97.08/vial/unit 8% below median
Anibret Terbinafine 1 % Cream 10gm 104342 PKR 252.11 PKR 25.21/g 10% below median
Anibret Terbinafine 125 mg Tablet 10's 104340 PKR 447.60 PKR 44.76/tablet 16% below median
Anibret Terbinafine 250 mg Tablet 10's 104341 PKR 715.02 PKR 71.50/tablet 14% below median
Astron Moxifloxacin 400 mg Tablet 5's 076351 PKR 873.67 PKR 174.73/tablet Near median
Astron Moxifloxacin 400 mg/250 mL IV infusion 250ml (Vial) 112722 PKR 1,258.10 PKR 5.03/mL 34% below median
Astron Moxifloxacin 5 mg/mL Ophthalmic drops 1x5ml 070818 PKR 342.35 PKR 68.47/mL 7% below median
Astron Moxifloxacin 5 mg/mL Ophthalmic drops 1x3ml 070818 PKR 237.74 PKR 79.25/mL 7% above median
Autoben Albendazole 200 mg Tablet 10's 104098 PKR 117.05 PKR 11.71/tablet 25% below median
Autoben Albendazole 200 mg Tablet 2's 104098 PKR 25.51 PKR 12.76/tablet 18% below median
Avlochlor-HS Hydroxychloroquine 200 mg Tablet 5x10's 104316 PKR 675.31 PKR 13.51/tablet 7% below median
Avlochlor-HS Hydroxychloroquine 200 mg Tablet 30's 104316 PKR 405.18 PKR 13.51/tablet 7% below median
Avlochlor-P Chloroquine 250 mg Tablet 50x10's 104317 PKR 637.76 PKR 1.28/tablet 18% below median
Avlochlor-P Chloroquine 50 mg/5 mL Syrup 60ml 104318 PKR 21.22 PKR 0.35/mL 7% above median
Cadlizo Linezolid 400 mg Tablet 12's 104238 PKR 2,190.99 PKR 182.58/tablet 21% below median
Cadlizo Linezolid 600 mg Tablet 12's 104239 PKR 3,835.74 PKR 319.65/tablet 19% below median
Ceftin Cefuroxime 250 mg Injection 1's 083957 PKR 54.35 PKR 54.35/vial/unit Near median
Ceftin Cefuroxime 750 mg Injection 1's 083958 PKR 194.15 PKR 194.15/vial/unit Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and DRAP-source records. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.